Outcomes Of New Human Amniotic Membrane-Derived Dry Matrix In The Management Of Persistent Corneal Epithelial Defects
Published 2022 - 40th Congress of the ESCRS
Reference: PP20.02 | Type: Free paper | DOI: 10.82333/xv19-2d91
Authors: Samer Hamada* 1 , Mohamed Elalfy 1
1Ophthalmology,Corneo Plastic Unit and Eye Bank, Queen Victoria Hospital,East Grinstead,United Kingdom
Purpose
To report the outcomes of using human amniotic membrane-derived dry matrix (AMDDM) in the management of persistent corneal epithelial defects (PEDs) of various etiologies.
Setting
Corneaoplastic Unit, Queen Victoria Hospital , East Grinstead, UK
Methods
A cohort study of 84 patients age range 7 to 92 years with 93 PEDs were treated with AMDDM (Omnigen® using OmniLenz® at two centers (Queen Victoria Hospital and Maidstone Hospital) in the UK. The main outcome measures were healing response of PED and time to heal after application of AMDDM.
Results
106 applications of AMDDM in 81 patients (52 males, 29 females) for different etiologies. 58% showed complete healing, and 28% partial decrease of size of PEDs with average treatment length 22.4±12.3 days. In patients with limbal stem cell deficiency (n=44; aniridia=12, chemical injury=9, Stevens-Johnson syndrome=10), 50% of PEDs showed complete healing and 27% showed partial healing. In patients with microbial keratitis (n=21) (bacterial: 13, fungal: 4, herpetic: 3, acanthamoeba: 1) 57% of PEDs showed complete healing and 33% partially healed. In keratoplasty (n=16), 56% showed complete healing and 31% partially healed. Vision remained stable in 59% and improved in 27%
Conclusions
AMDDM can be easily applied in the clinical setting and has demonstrated its efficiency as a new tool to treat persistent epithelial defects.